Very happy to share our study published @JCO_ASCO ! ascopubs.org/doi/full/10.120… ➡️Patients with mUC with NECTIN4 amplifications (occurring in app. 25%) show remarkable responses to single-agent EV, with a 96% objective response rate compared to 32% in non-amplified cases. NECTIN4 amplification predicts long-term survival benefits! ➡️Our data highlights the correlation between NECTIN4 targetability and EV response, which is consistent with findings obtained for other ADCs, such as the Her-2-targeting ADC trastuzumab-deruxtecan (T-DXd) ➡️Interestingly, NECTIN4 amplification occurs frequently across solid tumors (common also in TNBC & NSCLC!) ➡️NECTIN4 amplification has potential as a tumor-agnostic biomarker for NECTIN4-targeting therapies (like Her2-targeting T-DXd within DESTINY-PanTumor02 Phase II) ➡️ Conclusion: ADC response is dependent on target gene expression! We need better biomarker stratification for future trials in mUC, especially as the number of available ADCs increases (also Trop2, Her2..) ➡️Outlook: Validation of this biomarker for EV/P! Thanks to our great collaborators: @Markuseckstein3 @HolzelMichael @ViktorGruenwald @JoshMeeks @KuppeChristoph @IEO_HolzelLab @UniklinikBonn @UniBonn and to the support from @dfg_public (UroAgeCare!) & @EKFStiftung @BMBF_Bund Happy to discuss the data with the GU community! @ASCO @JCOPO_ASCO @OncoAlert @urotoday @PTarantinoMD @Uroweb @drenriquegrande @PGrivasMDPhD @amerseburger @DrYukselUrun @tompowles1 @Uromigos @OncoBellmunt @montypal @DrChoueiri @neerajaiims @shilpaonc @VPrasadMDMPH @sonpavde @DrRosenbergMSK @Dr_Aggen @jonchou05 @koshkin85

Excited to share our research that describes a variety of mechanisms that CD4+ T cells can employ to target melanoma!

🔬 After years of relentless dedication two incredible minds have achieved a major scientific award @dgukongress ! Their journey in testis and urothelial cancer research is a testament to the power of collaboration and perseverance. @niklas_kluemper @tim_nestler @urotoday